AstraZeneca have announced that the FDA has approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride extended-release) for the treatment of...
AstraZeneca’s Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adults with type-2 diabetes (T2D) as an adjunct to diet and exercise to improve glycaemic control